Arcus Biosciences Enters Material Definitive Agreement
Ticker: RCUS · Form: 8-K · Filed: Dec 18, 2025 · CIK: 1724521
Sentiment: neutral
Topics: material-definitive-agreement, financial-obligation
TL;DR
Arcus Bio just signed a big deal, creating a new financial obligation. Details in the 8-K.
AI Summary
On December 18, 2025, Arcus Biosciences, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, headquartered in Hayward, California, filed an 8-K report detailing this obligation.
Why It Matters
This filing indicates a significant new financial commitment or obligation for Arcus Biosciences, which could impact its financial health and future operations.
Risk Assessment
Risk Level: medium — Entering into material definitive agreements and creating financial obligations can introduce financial risks and impact the company's balance sheet.
Key Players & Entities
- Arcus Biosciences, Inc. (company) — Registrant
- December 18, 2025 (date) — Date of Report
- Hayward, California (location) — Principal Executive Offices
- 001-38419 (other) — Commission File Number
FAQ
What type of material definitive agreement did Arcus Biosciences enter into?
The filing states that Arcus Biosciences, Inc. entered into a material definitive agreement that resulted in the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement.
When was this agreement reported?
The agreement was reported on December 18, 2025.
What is the principal executive office address for Arcus Biosciences?
The principal executive offices are located at 3928 Point Eden Way, Hayward, California 94545.
What is the Commission File Number for Arcus Biosciences?
The Commission File Number for Arcus Biosciences is 001-38419.
What is the IRS Employer Identification Number for Arcus Biosciences?
The IRS Employer Identification Number for Arcus Biosciences is 47-3898435.
Filing Stats: 889 words · 4 min read · ~3 pages · Grade level 12.4 · Accepted 2025-12-18 16:05:43
Key Financial Figures
- $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share RCUS The New York Stock Excha
- $150.0 million — ment amends the terms for the remaining $150.0 million term loan commitments available under t
- $25.0 million — to customary terms and conditions, (a) $25.0 million is available at the Company's sole opti
- $50.0 million — n through September 15, 2026, (c) up to $50.0 million is available to the Company following t
- $200.0 million — mount of the term loan advances exceeds $200.0 million and beginning with the delivery of the
- $1.5 billion — rket capitalization greater or equal to $1.5 billion and "Qualified Cash" (defined as cash i
Filing Documents
- rcus-20251218.htm (8-K) — 27KB
- 0001724521-25-000122.txt ( ) — 139KB
- rcus-20251218.xsd (EX-101.SCH) — 2KB
- rcus-20251218_lab.xml (EX-101.LAB) — 21KB
- rcus-20251218_pre.xml (EX-101.PRE) — 12KB
- rcus-20251218_htm.xml (XML) — 3KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On December 18, 2025 (the "Closing Date"), Arcus Biosciences, Inc. (the "Company") entered into a First Amendment to the Loan and Security Agreement (the "First Amendment") with the several banks and other financial institutions or entities party thereto (the "Lenders"), as lenders, and Hercules Capital, Inc. ("Hercules"), as administrative agent and collateral agent. The First Amendment amended the terms of that certain Loan and Security Agreement, dated as of August 27, 2024, by and among the Company, Hercules and the Lenders (the "Loan Agreement"). The First Amendment amends the terms for the remaining $150.0 million term loan commitments available under the loan facility such that, subject to customary terms and conditions, (a) $25.0 million is available at the Company's sole option through March 15, 2026, (b) $25.0 million is available at the Company's sole option through September 15, 2026, (c) up to $50.0 million is available to the Company following the announcement of certain data from an ongoing Phase 3 pivotal study of its drug candidates ("Clinical Milestone") through the earlier of 90 days upon achieving the Clinical Milestone and March 15, 2028, which when taken together with an acceptable safety profile, support the filing of a Biologics License Application or New Drug Application to the U.S. Food and Drug Administration (the "FDA"), and (d) up to $50.0 million is available to the Company following the FDA's approval of either a Biologics License Application or New Drug Application ("Milestone I") through the earlier of 90 days upon achieving Milestone I and December 15, 2028. The First Amendment further extends the maturity date to September 1, 2030, with no further extension right. The First Amendment adds certain performance covenants in the event the aggregate outstanding principal amount of the term loan advances exceeds $200.0 million and beginning with the delivery of the quarterly fin
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARCUS BIOSCIENCES, INC. Date: December 18, 2025 By: /s/ Terry Rosen, Ph. D. Terry Rosen, Ph.D. Chief Executive Officer (Principal Executive Officer)